Graphite Bio, Inc. and Annexon, Inc. Enters into A Sublease Agreement for Office and Laboratory Space
November 16, 2021 at 04:01 pm EST
Share
On November 10, 2021, Graphite Bio, Inc. (the ?Company?) and Annexon, Inc. (the ?Sublandlord?) entered into a sublease agreement (the ?Sublease?) for office and laboratory space (the ?Premises?). The Premises consist of 18,326 square feet located at 1400 Sierra Point Parkway, Brisbane, California. In connection with its use of the Premises, the Company will also have the non-exclusive right to use a portion of the premises in the building consisting of 3,645 square feet of space leased by the Sublandlord from the master landlord. The term of the Sublease is expected to commence, subject to certain conditions, on or before December 1, 2021 (the ?Commencement Date?). The Sublease has a term of 24 months from the Commencement Date (the ?Term?), subject to earlier termination (i) by the Company in the event Sublease term has not commenced by January 1, 2022 or (ii) upon any termination of the master lease under which Sublandlord has leased the Premises from the master landlord. Under the Sublease, the Company is obligated to pay a base rent of $139,470.06 per month during the first twelve months of the Term and $144,351.51 per month for the remaining twelve months of the Term. The Company is also obligated to pay to the Sublandlord a pro-rated portion, as set forth in the Sublease, of certain direct expenses and the costs of utilities under the Sublandlord?s master lease with the master landlord. In addition, the Company has agreed to pay to the Sublandlord all costs of the Sublandlord incurred for performing any repairs or maintenance or providing other services to the Premises or the shared space specifically requested by the Company.
Annexon, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing a late-stage clinical platform of therapies for people living with classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Using its platform, it is identifying and characterizing the role of the complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Its lead candidate, ANX005, is an investigational monoclonal antibody (mAb), formulated for intravenous administration in a pivotal Phase III clinical trial for the treatment of patients with Guillain-Barre Syndrome (GBS). It is evaluating ANX007, an antigen-binding fragment (Fab), formulated for intravitreal administration, for the potential treatment of patients with geographic atrophy (GA). It is developing ANX1502, which is an oral small molecule for the treatment of autoimmune indications. It has developed ANX009, a C1q-blocking Fab formulated for subcutaneous delivery.